Blog Archives

The Clinical and Economic Impact of Inaccurate EGFR Mutation Tests in the Treatment of Metastatic Non-Small Cell Lung Cancer

June 30, 2017 – The below citation from PubMed addresses an vey important issue associated with genetic testing in theragenomic and personalized medicine. It is the question if the genetic test used to stage, classify, or determine treatability of a disease with a given drug is accurate.

Read more ›

Tags: , , , , , , , ,

This is it: First blood test to detect EGFR gene mutations in NSCLC

June 03, 2016 – This is a huge step in the application of theragenomic medicine in cancer patients in the quest to deliver highly individualized health care for patients. Thus, on June 01, the American Food & Drug Administration (FDA) approved the cobas EGFR Mutation Test v2,

Read more ›

Tags: , , , , , , , , , , ,

The use of Crizotinib (Xalkori) has been expanded to treat advanced NSCLC in the patient group who carries a ROS-1 gene alteration

March 14, 2015 – The American Food and Drug Administration (FDA) just approved Crizotinib (Xalkori) to treat the patient subpopulation with advanced (metastatic) non-small cell lung cancer (NSCLC) whose tumors have an ROS-1 gene alteration. Crizotinib (Xalkori) is the first and only FDA approved treatment for patients with ROS-1 positive NSCLC.

Read more ›

Tags: , , , , , ,

Osimertinib (Tagrissa) approved for non-smal cell lung cancer (NSCLC) patient subgroup carrying the EGFR T790M mutation

February 07, 2016 – The European Commission has approved once-daily Osimertinib (Tagrissa) for the treatment of patients with locally advanced or metastatic non-small-cell lung cancer (NSCLC) that is positive for the epidermal growth-factor receptor (EGFR) T790M mutation. This follows a positive review in December 2015.

Read more ›

Tags: , , , , , , ,

Alectinib (Alecensa) approved for treatment of patients with advanced (metastatic) ALK-positive non-small cell lung cancer (NSCLC)

December 12, 2015 – The American Food and Drug Administration today approved Alectinib (Alecensa) to treat people with advanced (metastatic) ALK-positive non-small cell lung cancer (NSCLC) whose disease has worsened after, or who could not tolerate treatment with, another therapy called Crizotinib (Xalkori).

Read more ›

Tags: , , , , , ,

Theragenomic medicine: FDA approves Osimertinib (Tagrisso) to treat patients with non-small cell lung cancer (NSCLC) who carry the EGFR mutation T790M

November 14, 2015 – The American Food and Drug Administration (FDA) just granted accelerated approval for an oral medication to treat patients with advanced non-small cell lung cancer (NSCLC). Osimertinib (Tagrisso) was approved for patients whose tumors have a specific epidermal growth factor receptor (EGFR) mutation (T790M) and whose disease has gotten worse after treatment with other EGFR-blocking therapy.

Read more ›

Tags: , , , , , , ,

Nivolumab (Opdivo) demonstrates survival benefit in squamous and non-squamous non-small cell lung cancer (NSCLC)

October 11, 2015 – In recent months, Nivolumab (Opdivo), a human IgG4 anti-PD-1 monoclonal antibody which targets the PD-1 receptor, had been approved first for the treatment of unresectable  or advanced (metastatic) melanoma and secondly for the treatment of advanced (metastatic) squamous non-small cell lung cancer (NSCLC).

Read more ›

Tags: , , , , , , , , , , ,

Remarkable: Pembrolizumab (Keytruda) now also for advanced non-small cell lung cancer (NSCLC)

October 06, 2015 –  Lung cancer is the leading cause of cancer death in the United States, with an estimated 221,200 new diagnoses and 158,040 deaths in 2015, according to the National Cancer Institute. Among lung cancers, non-small cell lung cancer (NSCLC) is the most common type of lung cancer.

Read more ›

Tags: , , , , , , , , ,

FDA Approves Companion Genetic Diagnostic Test for Erlotinib [Tarceva] in NSCLC

May 14, 2013 – The US Food and Drug Administration (FDA) today announced the approval of the cobas EGFR Mutation Test, a companion diagnostic for the cancer drug Erlotinib (Tarceva). This is the first FDA-approved companion diagnostic that can detect epidermal growth factor receptor (EGFR) gene mutations,

Read more ›

Tags: , , , , , , , , , ,

thasso: conditions

thasso: newest tweets

thasso: recent comments

thasso post: magazine

View my Flipboard Magazine.

thasso: categories

thasso: archives

thasso: simple chat

You must be a registered user to participate in this chat.

  • Findings in mice reveal possibilities for fetal drug therapy for deafness April 6, 2020
    New research led by hearing scientists at Oregon Health & Science University suggests an avenue to treat and prevent intractable genetic disorders before birth.
  • Study of rare genetic disorder that effects the eyes April 3, 2020
    Nagano prefecture is home to a group of people affected with a rare genetic neurodegenerative disorder called familial amyloid polyneuropathies (FAP). This disease impacts the gene encoding protein transthyretin (TTR) which is produced in the liver and also eyes. Liver transplants are often a treatment for this disease, but severe eyesight problems such as cloudiness […]
  • Natural sunscreen gene influences how we make vitamin D April 2, 2020
    Genetic variations in the skin can create a natural sunscreen, according to University of Queensland researchers investigating the genes linked with vitamin D.
  • Single mutation leads to big effects in autism-related gene April 2, 2020
    A new study in Neuron offers clues to why autism spectrum disorder (ASD) is more common in boys than in girls. National Institutes of Health scientists found that a single amino acid change in the NLGN4 gene, which has been linked to autism symptoms, may drive this difference in some cases. The study was conducted […]
  • Lifestyle changes could delay memory problems in old age, depending on our genes April 2, 2020
    Researchers from King's College London have shown that how we respond to changes in nutrients at a molecular level plays an important role in the aging process, and this is directed by some key genetic mechanisms.
  • Fiber consumption linked to lower breast cancer risk April 6, 2020
    Consuming a diet high in fiber was linked with a reduced incidence of breast cancer in an analysis of all relevant prospective studies. The findings are published early online in CANCER, a peer-reviewed journal of the American Cancer Society (ACS).
  • Stronger Atlantic currents drive temperate species to migrate towards the Arctic Ocean April 6, 2020
    The Arctic Ocean increasingly resembles the Atlantic, not only regarding its temperature but also the species that live there. However, scientists from the CNRS and Université Laval, Quebec showed that an unprecedented strengthening of Atlantic currents is playing a major role in this phenomenon called 'Atlantification.' The research team studied Emiliania huxleyi, a marine microalgae […]
  • Viruses don't have a metabolism; but some have the building blocks for one April 6, 2020
    'Giant viruses' are many times larger than typical viruses and have more complex genomes. Using publicly available metagenome data, researchers at Virginia Tech assembled genomes for more than 500 giant viruses and found a surprising number of genes for cellular metabolic cycles, including glycolysis, gluconeogenesis, and the TCA cycle. Viruses may deploy these genes to […]
  • AI techniques used to improve battery health and safety April 6, 2020
    Researchers have designed a machine learning method that can predict battery health with 10x higher accuracy than current industry standard, which could aid in the development of safer and more reliable batteries for electric vehicles and consumer electronics.
  • Evaluating grip strength to identify early diabetes April 6, 2020
    A new study in the American Journal of Preventive Medicine, published by Elsevier, reports valuable new grip strength metrics that provide healthcare practitioners with an easy-to-perform, time-efficient screening tool for type 2 diabetes (T2DM).
Top